Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Underwriters exercised their additional-share option in full, purchasing 2,646,000 shares as part of the completed offering.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lycia Therapeutics (LYCA) closed its upsized initial public offering, raising approximately $365.1 million in gross proceeds before offering costs.
The company sold 20,286,000 common shares at $18.00 per share, including 2,646,000 additional shares purchased through the underwriters’ full exercise of their option. All shares were offered by Lycia. Gross proceeds exclude underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Select Market on October 23, 2026, under the symbol LYCA.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointCompleted upsized IPO raised approximately $365.1 million in gross proceeds before underwriting discounts, commissions and other offering expenses. 22% of market cap
Negative
- Major pointIssuance of 20,286,000 common shares at $18.00 each, including the fully exercised underwriters’ option, dilutes existing holders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the closing of its upsized initial public offering of 20,286,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,646,000 additional shares, at the initial public offering price of
Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering. LifeSci Capital acted as a passive book-running manager for the offering.
Registration statements relating to the securities issued and sold in the initial public offering have been filed with the Securities and Exchange Commission (the “SEC”) and became effective on October 22, 2026. A prospectus relating to and describing the terms of the initial public offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. The offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Lycia, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Lycia Therapeutics
Lycia Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. The company has advanced its proprietary LYTAC (Lysosomal Targeting Chimera) platform to generate cataLYTAC degraders, which are designed for repeated catalytic elimination of disease-causing proteins. The company’s lead candidates are LCA-0061, a cataLYTAC degrader of IgE for food allergy and other allergic diseases, and LCA-0321, a LYTAC degrader designed to selectively deplete the autoantibodies that cause Graves’ disease.
Lycia, headquartered in South San Francisco, was founded on the transformational work of Nobel laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University.
CONTACT: Company Inquiries:
info@lyciatx.com
Media:
Jennifer Price
The Grace Group
jenprice@gracegroup.us
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did Lycia Therapeutics raise in its IPO, and at what price?
Lycia raised approximately $365.1 million in gross proceeds at $18.00 per share. The completed offering comprised 20,286,000 common shares, including 2,646,000 additional shares purchased under the underwriters’ fully exercised option. Gross proceeds are before underwriting discounts and commissions and other offering expenses.